236 related articles for article (PubMed ID: 28378457)
1. DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancer.
Takane K; Akagi K; Fukuyo M; Yagi K; Takayama T; Kaneda A
Cancer Med; 2017 May; 6(5):1023-1035. PubMed ID: 28378457
[TBL] [Abstract][Full Text] [Related]
2. Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes.
Kaneda A; Yagi K
Cancer Sci; 2011 Jan; 102(1):18-24. PubMed ID: 21159060
[TBL] [Abstract][Full Text] [Related]
3. Intermediate- and low-methylation epigenotypes do not correspond to CpG island methylator phenotype (low and -zero) in colorectal cancer.
Karpinski P; Walter M; Szmida E; Ramsey D; Misiak B; Kozlowska J; Bebenek M; Grzebieniak Z; Blin N; Laczmanski L; Sasiadek MM
Cancer Epidemiol Biomarkers Prev; 2013 Feb; 22(2):201-8. PubMed ID: 23175427
[TBL] [Abstract][Full Text] [Related]
4. RAS/RAF mutations and their associations with epigenetic alterations for distinct pathways in Vietnamese colorectal cancer.
Ta TV; Nguyen QN; Chu HH; Truong VL; Vuong LD
Pathol Res Pract; 2020 Apr; 216(4):152898. PubMed ID: 32089414
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological Features and Prognostic Value of KRAS/NRAS/BRAF Mutations in Colorectal Cancer Patients of Central China.
Chang XN; Shang FM; Jiang HY; Chen C; Zhao ZY; Deng SH; Fan J; Dong XC; Yang M; Li Y; Cai KL; Liu L; Liu HL; Nie X
Curr Med Sci; 2021 Feb; 41(1):118-126. PubMed ID: 33582915
[TBL] [Abstract][Full Text] [Related]
7. Two subtypes of colorectal tumor with distinct molecular features in familial adenomatous polyposis.
Takane K; Matsusaka K; Ota S; Fukuyo M; Yue Y; Nishimura M; Sakai E; Matsushita K; Miyauchi H; Aburatani H; Nakatani Y; Takayama T; Matsubara H; Akagi K; Kaneda A
Oncotarget; 2016 Dec; 7(51):84003-84016. PubMed ID: 27563825
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features.
Ang PW; Loh M; Liem N; Lim PL; Grieu F; Vaithilingam A; Platell C; Yong WP; Iacopetta B; Soong R
BMC Cancer; 2010 May; 10():227. PubMed ID: 20492682
[TBL] [Abstract][Full Text] [Related]
9. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors.
Sakai E; Ohata K; Chiba H; Matsuhashi N; Doi N; Fukushima J; Endo H; Takahashi H; Tsuji S; Yagi K; Matsusaka K; Aburatani H; Nakajima A; Kaneda A
Int J Cancer; 2014 Oct; 135(7):1586-95. PubMed ID: 24590867
[TBL] [Abstract][Full Text] [Related]
10. Three DNA methylation epigenotypes in human colorectal cancer.
Yagi K; Akagi K; Hayashi H; Nagae G; Tsuji S; Isagawa T; Midorikawa Y; Nishimura Y; Sakamoto H; Seto Y; Aburatani H; Kaneda A
Clin Cancer Res; 2010 Jan; 16(1):21-33. PubMed ID: 20028768
[TBL] [Abstract][Full Text] [Related]
11. Molecular Profiling Based on KRAS/BRAF Mutation, Methylation, and Microsatellite Statuses in Serrated Lesions.
Sugai T; Eizuka M; Fujita Y; Kawasaki K; Yamamoto E; Ishida K; Yamano H; Suzuki H; Matsumoto T
Dig Dis Sci; 2018 Oct; 63(10):2626-2638. PubMed ID: 29974407
[TBL] [Abstract][Full Text] [Related]
12. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations.
Ogura T; Kakuta M; Yatsuoka T; Nishimura Y; Sakamoto H; Yamaguchi K; Tanabe M; Tanaka Y; Akagi K
Oncol Rep; 2014 Jul; 32(1):50-6. PubMed ID: 24806883
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study.
Palomba G; Doneddu V; Cossu A; Paliogiannis P; Manca A; Casula M; Colombino M; Lanzillo A; Defraia E; Pazzola A; Sanna G; Putzu C; Ortu S; Scartozzi M; Ionta MT; Baldino G; Sarobba G; Capelli F; Sedda T; Virdis L; Barca M; Gramignano G; Budroni M; Tanda F; Palmieri G
J Transl Med; 2016 Oct; 14(1):292. PubMed ID: 27737711
[TBL] [Abstract][Full Text] [Related]
15. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F
Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826
[TBL] [Abstract][Full Text] [Related]
16.
El Zaitouni S; Laraqui A; Ghaouti M; Benzekri A; Kettani F; Bajjou T; Sekhsokh Y; Benmokhtar S; Jafari M; Baba W; Oukabli M; El Annaz H; Abi R; Tagajdid MR; El Kochri S; Lahlou IA; Ameziane El Hassani R; Ennibi K
Cancer Control; 2024; 31():10732748241262179. PubMed ID: 38875469
[TBL] [Abstract][Full Text] [Related]
17. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
Yang L; Dong D; Fang M; Zhu Y; Zang Y; Liu Z; Zhang H; Ying J; Zhao X; Tian J
Eur Radiol; 2018 May; 28(5):2058-2067. PubMed ID: 29335867
[TBL] [Abstract][Full Text] [Related]
18. Common KRAS and NRAS gene mutations in sporadic colorectal cancer in Northeastern Iranian patients.
Hamzehzadeh L; Khadangi F; Ghayoor Karimiani E; Pasdar A; Kerachian MA
Curr Probl Cancer; 2018 Nov; 42(6):572-581. PubMed ID: 29921458
[TBL] [Abstract][Full Text] [Related]
19. Assessment of three epigenotypes in colorectal cancer by combined bisulfite restriction analysis.
Karpinski P; Szmida E; Misiak B; Ramsey D; Leszczynski P; Bebenek M; Sedziak T; Grzebieniak Z; Jonkisz A; Lebioda A; Sasiadek MM
Mol Carcinog; 2012 Dec; 51(12):1003-8. PubMed ID: 22006538
[TBL] [Abstract][Full Text] [Related]
20. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
